Interiglin 0.75mg/ml Infusion
Marketer
MSD Pharmaceuticals Pvt Ltd
Salt Composition
Eptifibatide (0.75mg/ml)
Overview Interiglin 0.75mg/ml Infusion
CardioGuard 0.75mg/ml infusion is an anticoagulant that inhibits the development of dangerous blood clots. It's employed in the treatment of myocardial infarction and to prevent thrombosis during angioplasty (a procedure enhancing coronary blood flow). CardioGuard 0.75mg/ml infusion is administered under strict medical supervision. Dosage and treatment length are determined by your physician. Continue all prescribed medications for ongoing conditions, even after receiving this infusion. A potential side effect is thrombocytopenia, increasing bleeding risk. Report any petechiae, hematuria, or melena (blood in vomit, urine, or stool) immediately. Hypotension is another possible adverse effect. Your doctor will discuss the advantages and potential drawbacks before administration. Caution is advised for certain individuals. Prior to administration, disclose any bleeding disorders, hepatic or renal impairment, pregnancy, breastfeeding, or other concurrent medications.
Uses of Interiglin 0.75mg/ml Infusion
Thrombosis prophylaxis | Myocardial infarction prevention
Major Benefits of Interiglin 0.75mg/ml Infusion:
Administering this medication will be handled by your physician or their designated nurse; self-medication is strictly prohibited.
Common Side effects of Interiglin 0.75mg/ml Infusion:
- Bleeding
- Decreased blood pressure
How to use Interiglin 0.75mg/ml Infusion:
This medication will be administered by your healthcare provider. Self-medication is strongly discouraged.
How Interiglin 0.75mg/ml Infusion works:
Intraplatelet aggregation inhibitor, Interiglin 0.75mg/ml infusion, functions by suppressing platelet adhesion, consequently reducing the risk of adverse thrombus development.
SAFETY ADVICE
AlcoholCONSULT YOUR DOCTOR
Alcohol consumption alongside Interiglin 0.75mg/ml Infusion may pose unknown safety risks. Seek medical advice before combining them.
PregnancySAFE IF PRESCRIBED
The intravenous administration of Interiglin at a concentration of 0.75mg/ml is typically deemed safe for pregnant individuals. Preclinical trials using animal models revealed minimal or absent harm to the fetus; nevertheless, clinical data in humans remain scarce.
Breast feedingCAUTION
Maternal use of Interiglin 0.75mg/ml Infusion necessitates caution during lactation. Breastfeeding is advised against until treatment concludes and the medication is fully cleared from the mother's system.
DrivingNOT RELEVANT
Interiglin 0.75mg/ml Infusion is exclusively administered to hospitalized individuals.
KidneyCAUTION
Patients with kidney impairment should receive Interiglin 0.75mg/ml Infusion cautiously, potentially requiring dose modification. Physician consultation is advised. Interiglin 0.75mg/ml Infusion is contraindicated in individuals with severe kidney disease.
LiverCONSULT YOUR DOCTOR
Data regarding the administration of Interiglin 0.75mg/ml Infusion to individuals with hepatic impairment is scarce. Physician consultation is advised. Interiglin 0.75mg/ml Infusion is contraindicated in patients exhibiting severe liver dysfunction.
What if you forget to take Interiglin 0.75mg/ml Infusion :
Omit Interiglin 0.75mg/ml Infusion doses necessitate physician consultation.
Facts to Know About Interiglin 0.75mg/ml Infusion
| Label | Value |
|---|---|
| Chemical Type | Amino acid and peptide analogs |
| Developing Habits | No. |
| Treatment Category | KINSHIP |
| Actions | IIb/IIIa receptor antagonists |
3,018 People bought this recently